JMI Laboratories

Recent papers from JMI Laboratories

1. Activity of manogepix and comparator antifungal agents against uncommon filamentous fungal isolates collected in a global surveillance programMicrobiology Spectrum · 2026
2. Challenges in establishing epidemiological cut-off values for the Burkholderia cepacia complexJournal of Clinical Microbiology · 2026
3. Rabbit models of hip dysplasia: a narrative reviewLaboratory Animal Research · 2026
4. Establishment of epidemiological cutoff values against Purpureocillium lilacinumJournal of Clinical Microbiology · 2026
5. Evaluation of cefiderocol trailing and other unclear susceptibility testing endpoints for Acinetobacter spp.Journal of Clinical Microbiology · 2026
6. Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016–2024)Journal of Antimicrobial Chemotherapy · 2026
7. In vitro activity of cefiderocol against highly resistant Gram-negative pathogens collected in the SENTRY Surveillance Program between 2020 and 2024Journal of Global Antimicrobial Resistance · 2026
8. Characterization of gepotidacin activity, including in vitro kill kinetics, checkerboard, and PAE/SME testing against gram-positive and gram-negative bacteriaMicrobiology Spectrum · 2026
9. A Ten-Year Trend of Antimicrobial Resistance in Pseudomonas aeruginosa From United States Medical Centers: Results From the INFORM Surveillance Program (2015–2024)Open Forum Infectious Diseases · 2026
10. Multisite evaluation of blAST, a direct-from-urine phenotypic antimicrobial susceptibility test, compared with reference broth microdilutionDiagnostic Microbiology and Infectious Disease · 2026
11. Activity of isavuconazole and comparator agents against pediatric isolates from invasive fungal infectionsJournal of the Pediatric Infectious Diseases Society · 2026
12. Reduced Activity of Triazole Antifungal Agents Against Aspergillus tubingensis From a Global Collection of Genomically‐Characterized Aspergillus Section Nigri Clinical Isolates (2020–2023)Mycoses · 2026
13. Why we do what we do: a survey of ID providers about oral antibioticsAntimicrobial Stewardship & Healthcare Epidemiology · 2026
14. Multidrug-Resistant Enterobacterales in United States Hospitals: Frequency and Susceptibility to Newer β-Lactamase Inhibitor Combinations (2020–2024)International Journal of Antimicrobial Agents · 2026
15. Determination of frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of gram-positive and gram-negative organisms.2026
16. Total Ankle Arthroplasty Polyethylene Wear Varies With Implant Type and Mode of FailureFoot & Ankle Specialist · 2026
17. In Vitro Antimicrobial Activity of Ceftobiprole and Comparator Agents Against Streptococcus pneumoniae Responsible for Lower Respiratory Tract Infections in the United States (2016–2020), Including Resistant Subsets and Select SerotypesAntibiotics · 2026
18. Antimicrobial Susceptibility of Pseudomonas aeruginosa from Elderly Patients in Intensive Care Units of United States Medical Centers (2021–2025)Antibiotics · 2026
19. Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With FibromyalgiaJAMA Network Open · 2026
20. In vitro activity of furazidin and comparator agents against bacterial isolates from urinary tract infectionsEuropean Journal of Clinical Microbiology & Infectious Diseases · 2026